Bai Yanhua, Guo Ting, Niu Dongfeng, Zhu Yanli, Ren Wenhao, Yao Qian, Huang Xiaozheng, Feng Qin, Wang Tianxiao, Ma Xiuli, Ji Xinqiang
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China.
Division of Gastrointestinal Cancer Translational Research Laboratory, Peking University Cancer Hospital & Institute, Beijing, China.
Virchows Arch. 2022 Dec;481(6):903-911. doi: 10.1007/s00428-022-03390-9. Epub 2022 Aug 3.
Immunotherapy shows prospects in treating advanced medullary thyroid carcinoma although controversial reports are present. Recently, histological grading has been applied to medullary thyroid carcinoma by the Ki-67 index, mitotic figures, and tumor necrosis. However, the interrelation of PD-L1 expression, the Ki-67 index, and major genetic alterations of sporadic medullary thyroid carcinoma has not been fully reported. We examined the expression of PD-L1 (SP142 and 22C3) and the Ki-67 index immunohistologically and detected the major genetic alterations by next-generation sequencing in a cohort of sporadic medullary thyroid carcinomas, studied their survival impact, and discussed their interrelation. We identified that a high Ki-67 index (> 2%) and positive RET M918T mutation were correlated with poor disease-free survival but were not correlated with PD-L1 expression. All PD-L1 positive tumors were RET M918T mutation negative, and PD-L1 expression was positively correlated with HRAS mutation. The Ki-67 index was correlated with neither PD-L1 expression nor major genetic alterations. Our results indicate that immunotherapy targeting PD-L1/PD-1 might be more effective for patients with sporadic medullary thyroid carcinoma harboring HRAS mutations.
尽管存在争议性报道,但免疫疗法在治疗晚期甲状腺髓样癌方面显示出前景。最近,通过Ki-67指数、有丝分裂象和肿瘤坏死情况对甲状腺髓样癌进行了组织学分级。然而,散发性甲状腺髓样癌的PD-L1表达、Ki-67指数与主要基因改变之间的相互关系尚未得到充分报道。我们通过免疫组织化学方法检测了散发性甲状腺髓样癌队列中PD-L1(SP142和22C3)的表达及Ki-67指数,并通过下一代测序检测了主要基因改变,研究了它们对生存的影响,并探讨了它们之间的相互关系。我们发现,高Ki-67指数(>2%)和RET M918T阳性突变与无病生存期差相关,但与PD-L1表达无关。所有PD-L1阳性肿瘤均为RET M918T突变阴性,且PD-L1表达与HRAS突变呈正相关。Ki-67指数与PD-L1表达及主要基因改变均无相关性。我们的结果表明,针对PD-L1/PD-1的免疫疗法可能对携带HRAS突变的散发性甲状腺髓样癌患者更有效。